OA 235i
Alternative Names: OA-235iLatest Information Update: 03 Mar 2023
At a glance
- Originator Oasis Pharmaceuticals
- Developer Mayo Clinic; National Institute of Diabetes and Digestive and Kidney Diseases; Oasis Pharmaceuticals
- Class Hepatoprotectants
- Mechanism of Action PAR 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Non-alcoholic steatohepatitis